PT1094834E - Composicao farmaceutica para o tratamento de dispepsia funcional e/ou da sindroma do intestino irritavel e nova utilizacao de substancias contidas nessa composicao - Google Patents

Composicao farmaceutica para o tratamento de dispepsia funcional e/ou da sindroma do intestino irritavel e nova utilizacao de substancias contidas nessa composicao

Info

Publication number
PT1094834E
PT1094834E PT99930089T PT99930089T PT1094834E PT 1094834 E PT1094834 E PT 1094834E PT 99930089 T PT99930089 T PT 99930089T PT 99930089 T PT99930089 T PT 99930089T PT 1094834 E PT1094834 E PT 1094834E
Authority
PT
Portugal
Prior art keywords
treatment
composition
pharmaceutical composition
functional
irritavel
Prior art date
Application number
PT99930089T
Other languages
English (en)
Inventor
Suad Efendic
Per Hellstrom
Original Assignee
Melacure Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melacure Therapeutics Ab filed Critical Melacure Therapeutics Ab
Publication of PT1094834E publication Critical patent/PT1094834E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PT99930089T 1998-06-11 1999-06-08 Composicao farmaceutica para o tratamento de dispepsia funcional e/ou da sindroma do intestino irritavel e nova utilizacao de substancias contidas nessa composicao PT1094834E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9802080A SE9802080D0 (sv) 1998-06-11 1998-06-11 Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein

Publications (1)

Publication Number Publication Date
PT1094834E true PT1094834E (pt) 2004-03-31

Family

ID=20411665

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99930089T PT1094834E (pt) 1998-06-11 1999-06-08 Composicao farmaceutica para o tratamento de dispepsia funcional e/ou da sindroma do intestino irritavel e nova utilizacao de substancias contidas nessa composicao

Country Status (19)

Country Link
US (1) US6348447B1 (pt)
EP (2) EP1405642A1 (pt)
JP (2) JP2002517468A (pt)
AT (1) ATE252912T1 (pt)
AU (1) AU738994B2 (pt)
CA (1) CA2321700C (pt)
CZ (1) CZ300873B6 (pt)
DE (1) DE69912434T2 (pt)
DK (1) DK1094834T3 (pt)
ES (1) ES2205845T3 (pt)
HU (1) HUP0103147A3 (pt)
NO (1) NO327738B1 (pt)
NZ (1) NZ506163A (pt)
PL (1) PL198802B1 (pt)
PT (1) PT1094834E (pt)
RU (1) RU2226402C2 (pt)
SE (1) SE9802080D0 (pt)
WO (1) WO1999064060A1 (pt)
ZA (1) ZA200004080B (pt)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE545652T1 (de) 1999-06-29 2012-03-15 Mannkind Corp Reinigung und stabilisierung von proteinen und peptiden in pharmaceutischen agentien
US9006175B2 (en) * 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
MXPA02009031A (es) 2000-03-14 2004-08-19 Amylin Pharmaceuticals Inc Efectos del peptido-1(7-36) tipo glucagon en la motilidad antro-piloro.duodenal.
EP1282436B1 (en) * 2000-05-19 2008-06-11 Amylin Pharmaceuticals, Inc. Treatment of acute coronary syndrome with glp-1
DK1463751T3 (da) 2001-12-21 2013-08-26 Human Genome Sciences Inc Albuminfusionsproteiner.
ES2614603T3 (es) 2002-02-20 2017-06-01 Emisphere Technologies, Inc. Procedimiento de administración de moléculas GLP-1
ES2300568T3 (es) 2002-03-20 2008-06-16 Mannkind Corporation Aparato de inhalacion.
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
EA008831B1 (ru) 2003-06-12 2007-08-31 Эли Лилли Энд Компани Слитые белки аналогов glp-1
DK1633774T3 (da) * 2003-06-18 2010-05-25 Tranzyme Pharma Inc Makrocykliske motilinreceptorantagonister
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
CA2575692C (en) 2004-08-20 2014-10-14 Mannkind Corporation Catalysis of diketopiperazine synthesis
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
JP2008536881A (ja) * 2005-04-21 2008-09-11 ガストロテック・ファルマ・アクティーゼルスカブ Ｇｌｐ−１分子と制吐剤との医薬製剤
AU2006247734B2 (en) 2005-05-13 2011-06-23 Eli Lilly And Company GLP-1 pegylated compounds
US8236759B2 (en) 2005-06-30 2012-08-07 Ipsen Pharma Sas GLP-1 pharmaceutical compositions
ES2532666T3 (es) * 2005-07-29 2015-03-30 Solasia Pharma K.K. Compuestos y métodos para el tratamiento del cáncer
CN104324362B (zh) 2005-09-14 2018-04-24 曼金德公司 以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
MX2008010721A (es) 2006-02-22 2008-09-01 Mannkind Corp Un metodo para mejorar las propiedades farmaceuticas de microparticulas que contienen dicetopiperazina y un agente activo.
RU2445972C2 (ru) * 2006-12-29 2012-03-27 Ипсен Фарма С.А.С. Фармацевтические композиции glp-1
US8236760B2 (en) * 2007-04-27 2012-08-07 Cedars-Sinsai Medical Center Use of GLP-1 receptor agonists for the treatment of short bowel syndrome
KR101736535B1 (ko) * 2007-10-24 2017-05-16 맨카인드 코포레이션 Ｇｌｐ-1에 의한 유해 효과의 예방 방법
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
RU2467741C2 (ru) * 2007-10-24 2012-11-27 Маннкайнд Корпорейшн Доставка активных веществ
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
US8424518B2 (en) 2008-06-13 2013-04-23 Mannkind Corporation Dry powder inhaler and system for drug delivery
AU2009261441B2 (en) 2008-06-17 2013-01-10 Glytech, Inc. Oligosaccharide chain added glp-1 peptide
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2216042A1 (en) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP-1 analogues pharmaceutical compositions
JP5667095B2 (ja) 2009-03-11 2015-02-12 マンカインド コーポレイション 吸入器の抵抗を測定するための装置、システムおよび方法
US8614185B2 (en) 2009-05-04 2013-12-24 Centocor Ortho Biotech Inc. Fusion proteins of alpha-MSH derivatives and Fc
JP5751641B2 (ja) 2009-05-06 2015-07-22 ヤンセン バイオテツク，インコーポレーテツド メラノコルチン受容体結合コンジュゲート
KR20180036807A (ko) 2009-06-12 2018-04-09 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
RU2540012C2 (ru) * 2009-07-29 2015-01-27 Дайити Санкио Компани, Лимитед Мотилин-подобное пептидное соединение, обладающее приданной ему трансмукозальной абсорбционной способностью
US20120264684A1 (en) 2009-10-30 2012-10-18 Yasuhiro Kajihara Glycosylated Form of Antigenic GLP-1 Analogue
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
WO2011123943A1 (en) 2010-04-09 2011-10-13 Mount Sinai Hospital Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
NZ603169A (en) 2010-04-27 2015-02-27 Zealand Pharma As Peptide conjugates of glp-1 receptor agonists and gastrin and their use
CA2801936C (en) 2010-06-21 2021-06-01 Mannkind Corporation Dry powder drug delivery system and methods
AU2011274229A1 (en) 2010-07-02 2013-01-10 Angiochem Inc. Short and D-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
CN103826988B (zh) 2011-04-01 2016-03-09 曼金德公司 用于药物药盒的泡罩包装
MY161450A (en) 2011-04-12 2017-04-14 Novo Nordisk As Double-acylated glp-1 derivatives
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AU2012328885B2 (en) 2011-10-24 2017-08-31 Mannkind Corporation Methods and compositions for treating pain
CA2853884A1 (en) 2011-11-03 2013-05-10 Zealand Pharma A/S Glp-1 receptor agonist peptide gastrin conjugates
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
RS64942B1 (sr) 2012-03-22 2024-01-31 Novo Nordisk As Kompozicije koje obuhvataju sredstvo za isporuku i njihova priprema
RS57727B1 (sr) 2012-03-22 2018-12-31 Novo Nordisk As Kompozicije glp-1 peptida i njihovo dobijanje
ES2871328T3 (es) 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
MY170671A (en) 2012-07-23 2019-08-26 Zealand Pharma As Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
CA2906817C (en) 2013-03-15 2022-01-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
MX2016000739A (es) 2013-07-18 2017-04-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
HUE039616T2 (hu) 2013-10-17 2019-01-28 Zealand Pharma As Acilezett glükagon analógok
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
BR112016009995B1 (pt) 2013-11-06 2023-04-18 Zealand Pharma A/S Compostos agonistas triplos glucagon-glp-1-gip
AU2014345569B2 (en) 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
CA2965732A1 (en) 2014-10-29 2016-05-06 Zealand Pharma A/S Gip agonist compounds and methods
KR101825048B1 (ko) 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
CA2975633A1 (en) 2015-02-11 2016-08-18 Gmax Biopharm Llc. Stable pharmaceutical solution formulation of glp-1r antibody fusion protein
KR20170137198A (ko) 2015-04-16 2017-12-12 질랜드 파마 에이/에스 아실화된 글루카곤 유사체
CN117384274A (zh) 2016-12-09 2024-01-12 西兰制药公司 酰化的glp-1/glp-2双重激动剂
BR112020014624A2 (pt) 2018-02-02 2020-12-08 Novo Nordisk A/S Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante
CN117126279A (zh) 2018-03-20 2023-11-28 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
CN112521501A (zh) 2019-09-18 2021-03-19 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147327A (en) * 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
US5994500A (en) * 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides

Also Published As

Publication number Publication date
NZ506163A (en) 2004-10-29
US6348447B1 (en) 2002-02-19
PL343104A1 (en) 2001-07-30
HUP0103147A3 (en) 2002-02-28
CZ300873B6 (cs) 2009-09-02
DE69912434T2 (de) 2004-05-06
NO20006194D0 (no) 2000-12-06
CA2321700A1 (en) 1999-12-16
NO327738B1 (no) 2009-09-14
ATE252912T1 (de) 2003-11-15
WO1999064060A1 (en) 1999-12-16
HUP0103147A2 (hu) 2002-01-28
AU738994B2 (en) 2001-10-04
EP1405642A1 (en) 2004-04-07
PL198802B1 (pl) 2008-07-31
JP2010270125A (ja) 2010-12-02
SE9802080D0 (sv) 1998-06-11
CA2321700C (en) 2011-05-03
CZ20004491A3 (en) 2001-05-16
DE69912434D1 (de) 2003-12-04
ZA200004080B (en) 2001-12-24
AU4669799A (en) 1999-12-30
JP2002517468A (ja) 2002-06-18
RU2226402C2 (ru) 2004-04-10
EP1094834A1 (en) 2001-05-02
DK1094834T3 (da) 2004-01-05
ES2205845T3 (es) 2004-05-01
NO20006194L (no) 2001-01-25
EP1094834B1 (en) 2003-10-29

Similar Documents

Publication Publication Date Title
PT1094834E (pt) Composicao farmaceutica para o tratamento de dispepsia funcional e/ou da sindroma do intestino irritavel e nova utilizacao de substancias contidas nessa composicao
RU2000133249A (ru) Фармацевтическая композиция для лечения функциональной диспепсии и/или синдрома раздраженной толстой кишки и новое применение веществ в ней
Frank et al. Surgical pathology of collateral ligamentous injuries of the thumb
NO984005L (no) Anvendelse av et farmas°ytisk preparat som omfatter et appetittundertrykkende peptid
ATE209923T1 (de) Pharmazeutische zusammensetzungen, welche ausgewählte lanthankarbonathydrate enthalten
AR022368A1 (es) Procedimiento para administrar peptidos insulinotropicos
NZ334270A (en) Glucagon like peptide (GLP-1), analogs and derivatives to treat post surgical catabolic changes and insulin resistance
EP1019072A4 (en) ASSISTANCE PROCESS FOR DIFFERENTIAL DIAGNOSIS AND TREATMENT OF AUTISM SYNDROME
WO2001068112A3 (en) Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
ZA975866B (en) Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases.
SE9800550D0 (sv) A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
PT758241E (pt) Utilizacao de certos derivados de acido metanobisfosfonico para impedir o desprendimento de proteses e a migracao de proteses
BR9809951A (pt) Método para tratamento da obesidade
ISELIN The flag flap
DK0470117T3 (da) Anvendelse af "calcitonin gene-related peptides" til fremstilling af lægemidler til behandling af erektile dysfunktioner
IS4510A (is) Peptíð p277 hliðstæður og lyfjasamsetningar sem innihalda þær, til meðhöndlunar eða sjúkdómsgreiningar á sykursýki
DK0668077T3 (da) Produkter, som indeholder G-CSF og TNF-bindende protein
KR970701724A (ko) 스타니어스 단백질인 스타니오칼신의 소체(Corpuscles of stannius protein, stanniocalcin)
Inoue et al. One-stage repair of skin and tendon digital defects using the arterialized venous flap with palmaris longus tendon: an additional four cases
NO982935D0 (no) Hyaluronsyre reseptor bindende middel og anvendelse derav
BR0014374A (pt) Combinação de loteprednol e agonistas do adrenorreceptor beta dois
EP0384302A3 (en) Use of ubenimex in the manufacture of a medicament for treating myelodysplastic syndrome
SE8501203D0 (sv) Mammal intestinal hormone precursor and its use
WO1998024421A3 (en) Use of dextrin sulphate for the treatment of highly vascular tumours